PRESCIENT THERAPEUTICS LIMITED - Announcements

4.26%

4.5¢

Market Cap $36.23M

Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PTX	Prescient Therapeutics - Investor Briefing		17/04/25	1.7MB	Share
PTX	PTX-100 receives U.S. FDA Fast Track Designation	PRICE SENSITIVE	16/04/25	215.66KB	Share
PTX	Initial Director's Interest Notice		11/04/25	146.12KB	Share
PTX	PTX appoints Melanie Farris as Non-Executive Director		10/04/25	180.7KB	Share
PTX	Final Director's Interest Notice		01/04/25	168.41KB	Share
PTX	Prescient Therapeutics - Investor Briefing		31/03/25	2.4MB	Share
PTX	PTX Opens First Clinical site for PTX-100 Phase 2a Study	PRICE SENSITIVE	26/03/25	184.98KB	Share
PTX	Change of Chief Medical Officer		24/03/25	147.13KB	Share
PTX	PTX-100 clinical data presented at leading TCL meeting		21/03/25	157.43KB	Share
PTX	Change of Director's Interest Notice		17/03/25	222.13KB	Share
PTX	Change of Board Chair		11/03/25	231.7KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	21/02/25	799.88KB	Share
PTX	December 2024 Quarterly Update and Appendix 4C - amended	PRICE SENSITIVE	31/01/25	465.2KB	Share
PTX	December 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/25	359.71KB	Share
PTX	OmniCAR technical issues resolved and program to progress		23/01/25	567.84KB	Share
PTX	Final Director's Interest Notice		22/01/25	163.32KB	Share
PTX	Notification regarding unquoted securities - PTX		22/01/25	18.49KB	Share
PTX	Notification of cessation of securities - PTX		13/01/25	12.82KB	Share
PTX	US FDA allows PTX-100 Ph2 trial	PRICE SENSITIVE	23/12/24	105.04KB	Share
PTX	Appointment of Chief Executive Officer	PRICE SENSITIVE	17/12/24	253.08KB	Share
PTX	Change of Director's Interest Notice		11/12/24	214.45KB	Share
PTX	Notification regarding unquoted securities - PTX		11/12/24	18.63KB	Share
PTX	Change of Director's Interest Notices x4		04/12/24	1.32MB	Share
PTX	Notification of cessation of securities - PTX		04/12/24	12.87KB	Share
PTX	Results of Annual General Meeting		14/11/24	657.74KB	Share
PTX	Chair and CEO AGM Presentation		14/11/24	1.92MB	Share
PTX	September 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/24	375.24KB	Share
PTX	Notice of Annual General Meeting/Proxy Form		14/10/24	1.67MB	Share
PTX	Change of Director's Interest Notice		03/10/24	184.14KB	Share
PTX	Notification of cessation of securities - PTX		02/10/24	12.96KB	Share
PTX	Prescient CEO to step down in early 2025	PRICE SENSITIVE	12/09/24	238.17KB	Share
PTX	PTX Presentation		05/09/24	2.34MB	Share
PTX	Appendix 4G and Corporate Governance Statement		26/08/24	595.36KB	Share
PTX	Appendix 4E and 2024 Annual Report	PRICE SENSITIVE	26/08/24	2.47MB	Share
PTX	June 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/07/24	621.63KB	Share
PTX	Initial Director's Interest Notice		05/07/24	156.43KB	Share
PTX	PTX appoints Dr Gavin Shepherd as Non-Executive Director		04/07/24	184.04KB	Share
PTX	Notification of cessation of securities - PTX		04/06/24	12.89KB	Share
PTX	Change of Director's Interest Notice		04/06/24	169.08KB	Share
PTX	PTX invited to present at international lymphoma forum		20/05/24	245.98KB	Share
PTX	March 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/04/24	392.22KB	Share
PTX	PTX100 Ph1b results to be presented at specialist congress		08/04/24	253.17KB	Share
PTX	Notification of cessation of securities - PTX		05/04/24	12.96KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/24	656.43KB	Share
PTX	December 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/24	2.53MB	Share
PTX	PTX-100 Spotlight Presentation		18/12/23	1.35MB	Share
PTX	PTX-100 Ph1b results show excellent safety & efficacy in TCL	PRICE SENSITIVE	11/12/23	1.3MB	Share
PTX	Prescient Receives $2.4 Million R&D Tax Rebate		28/11/23	605.26KB	Share
PTX	Results of Annual General Meeting		16/11/23	468.64KB	Share
PTX	Chair and CEO AGM Presentation		16/11/23	15.43MB	Share
PTX	PTX-100 abstract published online on ASH website		06/11/23	607.01KB	Share
PTX	September 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/23	1.32MB	Share
PTX	PTX results to be presented at world's largest blood meeting		17/10/23	1.16MB	Share
PTX	Notice of Annual General Meeting/Proxy Form		13/10/23	1.27MB	Share
PTX	Application for quotation of securities - PTX		31/08/23	24.99KB	Share
PTX	Section 708A Cleansing Notice		31/08/23	507.92KB	Share
PTX	Appendix 4G and Corporate Governance Statement		25/08/23	1.37MB	Share
PTX	Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	25/08/23	1.24MB	Share
PTX	June 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	27/07/23	6.49MB	Share
PTX	Application for quotation of securities - PTX		14/06/23	25.01KB	Share
PTX	Two PTX abstracts accepted at prestigious ISCT conference		16/05/23	897.76KB	Share
PTX	Initial Director's Interest Notice		15/05/23	243.47KB	Share
PTX	Notification regarding unquoted securities - PTX		15/05/23	27.54KB	Share
PTX	Experienced Pharma Executive Joins Prescient Board		15/05/23	1.16MB	Share
PTX	Notification of cessation of securities - PTX		05/05/23	22.3KB	Share
PTX	Change of Director's Interest Notices x3		02/05/23	430.43KB	Share
PTX	Application for quotation of securities - PTX		01/05/23	25.84KB	Share
PTX	Section 708A Cleansing Notice		01/05/23	483.08KB	Share
PTX	March 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	28/04/23	1.53MB	Share
PTX	Change of Director's Interest Notices x2		04/04/23	417.73KB	Share
PTX	Application for quotation of securities - PTX		04/04/23	25.05KB	Share
PTX	Exercise and Expiry of Listed Options		04/04/23	942.19KB	Share
PTX	Continued promising results in PTX-100 TCL trial	PRICE SENSITIVE	16/03/23	2.08MB	Share
PTX	FDA grants broader orphan drug status to PTX100 for TCLs	PRICE SENSITIVE	09/03/23	893.45KB	Share
PTX	Revised Securities Trading Policy		27/02/23	1.08MB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	24/02/23	1.58MB	Share
PTX	Notification of Expiry of Listed Options		22/02/23	2.08MB	Share
PTX	Application for quotation of securities - PTX		09/02/23	24.98KB	Share
PTX	December 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/01/23	1.19MB	Share
PTX	Application for quotation of securities - PTX		25/01/23	24.97KB	Share
PTX	Application for quotation of securities - PTX		05/01/23	24.97KB	Share
PTX	Change of Director's Interest Notice		14/12/22	268.38KB	Share
PTX	Notification of cessation of securities - PTX		14/12/22	23.25KB	Share
PTX	Section 708A Cleansing Notice		14/12/22	481.7KB	Share
PTX	Application for quotation of securities - PTX		14/12/22	26.42KB	Share
PTX	Application for quotation of securities - PTX		09/12/22	25.77KB	Share
PTX	Results of Annual General Meeting		29/11/22	898.94KB	Share
PTX	AGM Presentation	PRICE SENSITIVE	29/11/22	2.43MB	Share
PTX	Chair's Address to the 2022 Annual General Meeting		29/11/22	1.42MB	Share
PTX	Application for quotation of securities - PTX		15/11/22	25.77KB	Share
PTX	PTX Investor presentation and additional patient response		02/11/22	4.36MB	Share
PTX	September 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/22	1.37MB	Share
PTX	Notice of Annual General Meeting/Proxy Form		27/10/22	775.92KB	Share
PTX	PTX-100 Trial Update	PRICE SENSITIVE	25/10/22	4.01MB	Share
PTX	Application for quotation of securities - PTX		17/10/22	25.6KB	Share
PTX	Section 708A Cleansing Notice		17/10/22	369.44KB	Share
PTX	Application for quotation of securities - PTX		13/10/22	25.77KB	Share
PTX	Change of Director's Interest Notices x2		12/10/22	322.53KB	Share
PTX	Application for quotation of securities - PTX		11/10/22	25.52KB	Share
PTX	Proposed issue of securities - PTX		11/10/22	25.27KB	Share

PTX Prescient Therapeutics - Investor Briefing
17/04/25		1.7MB	Share
PTX PTX-100 receives U.S. FDA Fast Track Designation
16/04/25	PRICE SENSITIVE	215.66KB	Share
PTX Initial Director's Interest Notice
11/04/25		146.12KB	Share
PTX PTX appoints Melanie Farris as Non-Executive Director
10/04/25		180.7KB	Share
PTX Final Director's Interest Notice
01/04/25		168.41KB	Share
PTX Prescient Therapeutics - Investor Briefing
31/03/25		2.4MB	Share
PTX PTX Opens First Clinical site for PTX-100 Phase 2a Study
26/03/25	PRICE SENSITIVE	184.98KB	Share
PTX Change of Chief Medical Officer
24/03/25		147.13KB	Share
PTX PTX-100 clinical data presented at leading TCL meeting
21/03/25		157.43KB	Share
PTX Change of Director's Interest Notice
17/03/25		222.13KB	Share
PTX Change of Board Chair
11/03/25		231.7KB	Share
PTX Appendix 4D and Half Year Financial Report
21/02/25	PRICE SENSITIVE	799.88KB	Share
PTX December 2024 Quarterly Update and Appendix 4C - amended
31/01/25	PRICE SENSITIVE	465.2KB	Share
PTX December 2024 Quarterly Update and Appendix 4C
31/01/25	PRICE SENSITIVE	359.71KB	Share
PTX OmniCAR technical issues resolved and program to progress
23/01/25		567.84KB	Share
PTX Final Director's Interest Notice
22/01/25		163.32KB	Share
PTX Notification regarding unquoted securities - PTX
22/01/25		18.49KB	Share
PTX Notification of cessation of securities - PTX
13/01/25		12.82KB	Share
PTX US FDA allows PTX-100 Ph2 trial
23/12/24	PRICE SENSITIVE	105.04KB	Share
PTX Appointment of Chief Executive Officer
17/12/24	PRICE SENSITIVE	253.08KB	Share
PTX Change of Director's Interest Notice
11/12/24		214.45KB	Share
PTX Notification regarding unquoted securities - PTX
11/12/24		18.63KB	Share
PTX Change of Director's Interest Notices x4
04/12/24		1.32MB	Share
PTX Notification of cessation of securities - PTX
04/12/24		12.87KB	Share
PTX Results of Annual General Meeting
14/11/24		657.74KB	Share
PTX Chair and CEO AGM Presentation
14/11/24		1.92MB	Share
PTX September 2024 Quarterly Update and Appendix 4C
31/10/24	PRICE SENSITIVE	375.24KB	Share
PTX Notice of Annual General Meeting/Proxy Form
14/10/24		1.67MB	Share
PTX Change of Director's Interest Notice
03/10/24		184.14KB	Share
PTX Notification of cessation of securities - PTX
02/10/24		12.96KB	Share
PTX Prescient CEO to step down in early 2025
12/09/24	PRICE SENSITIVE	238.17KB	Share
PTX PTX Presentation
05/09/24		2.34MB	Share
PTX Appendix 4G and Corporate Governance Statement
26/08/24		595.36KB	Share
PTX Appendix 4E and 2024 Annual Report
26/08/24	PRICE SENSITIVE	2.47MB	Share
PTX June 2024 Quarterly Update and Appendix 4C
31/07/24	PRICE SENSITIVE	621.63KB	Share
PTX Initial Director's Interest Notice
05/07/24		156.43KB	Share
PTX PTX appoints Dr Gavin Shepherd as Non-Executive Director
04/07/24		184.04KB	Share
PTX Notification of cessation of securities - PTX
04/06/24		12.89KB	Share
PTX Change of Director's Interest Notice
04/06/24		169.08KB	Share
PTX PTX invited to present at international lymphoma forum
20/05/24		245.98KB	Share
PTX March 2024 Quarterly Update and Appendix 4C
30/04/24	PRICE SENSITIVE	392.22KB	Share
PTX PTX100 Ph1b results to be presented at specialist congress
08/04/24		253.17KB	Share
PTX Notification of cessation of securities - PTX
05/04/24		12.96KB	Share
PTX Appendix 4D and Half Year Financial Report
23/02/24	PRICE SENSITIVE	656.43KB	Share
PTX December 2023 Quarterly Update and Appendix 4C
31/01/24	PRICE SENSITIVE	2.53MB	Share
PTX PTX-100 Spotlight Presentation
18/12/23		1.35MB	Share
PTX PTX-100 Ph1b results show excellent safety & efficacy in TCL
11/12/23	PRICE SENSITIVE	1.3MB	Share
PTX Prescient Receives $2.4 Million R&D Tax Rebate
28/11/23		605.26KB	Share
PTX Results of Annual General Meeting
16/11/23		468.64KB	Share
PTX Chair and CEO AGM Presentation
16/11/23		15.43MB	Share
PTX PTX-100 abstract published online on ASH website
06/11/23		607.01KB	Share
PTX September 2023 Quarterly Update and Appendix 4C
31/10/23	PRICE SENSITIVE	1.32MB	Share
PTX PTX results to be presented at world's largest blood meeting
17/10/23		1.16MB	Share
PTX Notice of Annual General Meeting/Proxy Form
13/10/23		1.27MB	Share
PTX Application for quotation of securities - PTX
31/08/23		24.99KB	Share
PTX Section 708A Cleansing Notice
31/08/23		507.92KB	Share
PTX Appendix 4G and Corporate Governance Statement
25/08/23		1.37MB	Share
PTX Appendix 4E and 2023 Annual Report
25/08/23	PRICE SENSITIVE	1.24MB	Share
PTX June 2023 Quarterly Update and Appendix 4C
27/07/23	PRICE SENSITIVE	6.49MB	Share
PTX Application for quotation of securities - PTX
14/06/23		25.01KB	Share
PTX Two PTX abstracts accepted at prestigious ISCT conference
16/05/23		897.76KB	Share
PTX Initial Director's Interest Notice
15/05/23		243.47KB	Share
PTX Notification regarding unquoted securities - PTX
15/05/23		27.54KB	Share
PTX Experienced Pharma Executive Joins Prescient Board
15/05/23		1.16MB	Share
PTX Notification of cessation of securities - PTX
05/05/23		22.3KB	Share
PTX Change of Director's Interest Notices x3
02/05/23		430.43KB	Share
PTX Application for quotation of securities - PTX
01/05/23		25.84KB	Share
PTX Section 708A Cleansing Notice
01/05/23		483.08KB	Share
PTX March 2023 Quarterly Update and Appendix 4C
28/04/23	PRICE SENSITIVE	1.53MB	Share
PTX Change of Director's Interest Notices x2
04/04/23		417.73KB	Share
PTX Application for quotation of securities - PTX
04/04/23		25.05KB	Share
PTX Exercise and Expiry of Listed Options
04/04/23		942.19KB	Share
PTX Continued promising results in PTX-100 TCL trial
16/03/23	PRICE SENSITIVE	2.08MB	Share
PTX FDA grants broader orphan drug status to PTX100 for TCLs
09/03/23	PRICE SENSITIVE	893.45KB	Share
PTX Revised Securities Trading Policy
27/02/23		1.08MB	Share
PTX Appendix 4D and Half Year Financial Report
24/02/23	PRICE SENSITIVE	1.58MB	Share
PTX Notification of Expiry of Listed Options
22/02/23		2.08MB	Share
PTX Application for quotation of securities - PTX
09/02/23		24.98KB	Share
PTX December 2022 Quarterly Update and Appendix 4C
25/01/23	PRICE SENSITIVE	1.19MB	Share
PTX Application for quotation of securities - PTX
25/01/23		24.97KB	Share
PTX Application for quotation of securities - PTX
05/01/23		24.97KB	Share
PTX Change of Director's Interest Notice
14/12/22		268.38KB	Share
PTX Notification of cessation of securities - PTX
14/12/22		23.25KB	Share
PTX Section 708A Cleansing Notice
14/12/22		481.7KB	Share
PTX Application for quotation of securities - PTX
14/12/22		26.42KB	Share
PTX Application for quotation of securities - PTX
09/12/22		25.77KB	Share
PTX Results of Annual General Meeting
29/11/22		898.94KB	Share
PTX AGM Presentation
29/11/22	PRICE SENSITIVE	2.43MB	Share
PTX Chair's Address to the 2022 Annual General Meeting
29/11/22		1.42MB	Share
PTX Application for quotation of securities - PTX
15/11/22		25.77KB	Share
PTX PTX Investor presentation and additional patient response
02/11/22		4.36MB	Share
PTX September 2022 Quarterly Update and Appendix 4C
31/10/22	PRICE SENSITIVE	1.37MB	Share
PTX Notice of Annual General Meeting/Proxy Form
27/10/22		775.92KB	Share
PTX PTX-100 Trial Update
25/10/22	PRICE SENSITIVE	4.01MB	Share
PTX Application for quotation of securities - PTX
17/10/22		25.6KB	Share
PTX Section 708A Cleansing Notice
17/10/22		369.44KB	Share
PTX Application for quotation of securities - PTX
13/10/22		25.77KB	Share
PTX Change of Director's Interest Notices x2
12/10/22		322.53KB	Share
PTX Application for quotation of securities - PTX
11/10/22		25.52KB	Share
PTX Proposed issue of securities - PTX
11/10/22		25.27KB	Share

REFRESH

1 2 3 4 5

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.5¢		Change -0.002(4.26%)		Mkt cap ! $36.23M

Open	High	Low	Value	Volume
4.7¢	4.7¢	4.5¢	$3.023K	65.69K

Buyers (Bids)

No.	Vol.	Price($)
2	26147	4.5¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	100000	1

View Market Depth

No.	Vol.	Price($)
2	26147	0.045
4	120290	0.043
2	155476	0.042
3	204000	0.041
14	1327931	0.040

Price($)	Vol.	No.
0.048	100000	1
0.049	240703	3
0.051	116601	3
0.052	215000	2
0.053	300000	1

Last trade - 16.10pm 23/04/2025 (20 minute delay)

PTX (ASX) Chart

PRESCIENT THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available